Most Read Articles
4 days ago
Prenatal and postpartum vitamin D supplementation does not appear to improve foetal or infant growth, a study reports.
6 days ago
Excessive daytime sleepiness appears to increase the long-term risk of amyloid β (Aβ) deposition, a recent study has shown.
6 days ago
Substituting diets high in carbohydrates with those high in monounsaturated fatty acids in the context of low saturated fatty acids do not appear to yield favourable effects on blood pressure, according to a meta-analysis.
12 Sep 2018
Among obese and overweight adults with type 2 diabetes mellitus, women appear to be less likely than men to develop mild cognitive impairment, independent of traditional risk factors, a recent study has shown.

Fidaxomicin therapy most effective during first episode of C. difficile infection

14 Jan 2018

Patients with a first episode of Clostridium difficile infection (CDI) are likely to respond to treatment with fidaxomicin with no recurrences, a recent study has shown. On the other hand, those with prior CDI episodes are less likely to respond, especially with >1 prior episode, and more likely to recur, which suggests a greater clinical benefit of fidaxomicin earlier in the course of CDI.

There were 81 patients (median age 55.9 years; 53 percent female; 26 percent with inflammatory bowel disease) included in the study, of which 90 percent responded to fidaxomicin therapy. Prior CDI episodes were fewer (p=0.01) in responders (median, 1; range, 0‒8) vs nonresponders (median, 2.5; range, 1‒8). Response was 100 percent after a first CDI episode, 96 percent after one prior episode, and 82 percent after two or more (p=0.02).

There was a 19-percent recurrence rate. Patients who did not recur had fewer prior episodes of CDI (median 1; range 0‒6) than those with a recurrence (median, 2; range, 1‒8; p=0.005). Recurrence was 0 percent after a first episode, 23 percent after one prior episode, and 29 percent after two or more (p=0.005).

All patients with inflammatory bowel disease, as a response, either improved their symptoms or had a negative C. difficile test. Recurrence occurred in 19 percent.

The investigators included all CDI cases treated with fidaxomicin at three referral centres over a 4-year period. The definition of ‘response’ was resolution of diarrhoea, and ‘recurrence’ was defined by CDI recurrence within 8 weeks of the end of treatment.

“Fidaxomicin is a new antibiotic used to treat CDI,” according to the investigators. 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Prenatal and postpartum vitamin D supplementation does not appear to improve foetal or infant growth, a study reports.
6 days ago
Excessive daytime sleepiness appears to increase the long-term risk of amyloid β (Aβ) deposition, a recent study has shown.
6 days ago
Substituting diets high in carbohydrates with those high in monounsaturated fatty acids in the context of low saturated fatty acids do not appear to yield favourable effects on blood pressure, according to a meta-analysis.
12 Sep 2018
Among obese and overweight adults with type 2 diabetes mellitus, women appear to be less likely than men to develop mild cognitive impairment, independent of traditional risk factors, a recent study has shown.